Feladilimab clinical trials
How each study uses feladilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2019 (4)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Belantamab mafodotin (1) · Docetaxel (1) · Belrestotug (1) · Nelistotug (1)
Studies
Open first, then newest update. How each study uses feladilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMMActive, not recruitingPhase 1/2GlaxoSmithKlineNCT07217119Written as Feladilimab
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)CompletedPhase 2GlaxoSmithKlineNCT03739710Written as Feladilimab
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2TerminatedPhase 2GlaxoSmithKlineNCT06790303Written as Feladilimab
- Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)CompletedPhase 1GlaxoSmithKlineNCT02723955Written as feladilimab (GSK3359609)
- Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedPhase 3GlaxoSmithKlineNCT04428333Written as Feladilimab
- GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid TumorsCompletedPhase 1/2GlaxoSmithKlineNCT03693612Written as feladilimab
- Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedPhase 3GlaxoSmithKlineNCT04128696Written as feladilimab
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1CompletedPhase 2GlaxoSmithKlineNCT05553808Written as Feladilimab
Given beside what is tested · 2 — feladilimab is usual care or a partner of the new treatment
- Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Active, not recruitingPhase 1/2GlaxoSmithKlineNCT04126200Written as Feladilimab
- Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid TumorsCompletedPhase 1GlaxoSmithKlineNCT03447314Written as GSK3359609
Codes
What other systems call feladilimab · ClinicalTrials.gg INT017500
- UNII (FDA) OUP4QB2A3RFELADILIMABOne source FDA
- NCI Thesaurus C126804FeladilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | OUP4QB2A3R | FELADILIMAB | One source FDA |
| NCI Thesaurus | C126804 | Feladilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.